CHMP backs Fortvita's PD-1 antibody Zybrivo in first-line non-squamous NSCLC

What happened

On 12 November 2026 the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on Zybrivo (sintilimab), a PD-1 antibody from Fortvita Biologics. The committee recommends marketing authorisation for adults with non-squamous non-small cell lung cancer (NSCLC), as first-line treatment in combination with chemotherapy.

The records give us the product, sponsor, population, line of therapy and combination partner category. They do not give the pivotal trial, efficacy or safety results, any biomarker restriction, the chemotherapy backbone, or any conditions attached to the authorisation. Those details usually appear in the summary of opinion and the European public assessment report (EPAR), so for now they are not known.

Why it matters

A CHMP opinion is a recommendation, not a licence. The European Commission normally issues a legally binding decision on it within about two months. Only then can the product be marketed across the EU and EEA. For Fortvita, the opinion is the main scientific hurdle cleared. For competitors and payers, it signals that another PD-1 option may soon be available in a crowded first-line setting.

The records do not say how Zybrivo compares with existing PD-1 or PD-L1 regimens, and we will not speculate. Whether it brings any differentiation, such as data package, dosing or price, is not yet known. Those factors will shape how health technology assessment bodies and national payers treat it after authorisation.

The wider regulatory picture

The Zybrivo opinion was one of several CHMP outcomes reported on the same day. Novartis received a positive opinion for Cosentyx (secukinumab) in adolescents aged 12 and over with moderate-to-severe hidradenitis suppurativa who responded inadequately to conventional systemic therapy. Roche's Gazyvaro (obinutuzumab) was backed as add-on therapy for adults with moderate-to-severe, active, autoantibody-positive systemic lupus erythematosus despite standard therapy, based on phase III ALLEGORY data. Both are extensions of existing products, whereas Zybrivo is a recommendation for a new marketing authorisation. That difference matters for what follows: a new product faces product-launch obligations, such as pharmacovigilance set-up, risk management and supply readiness, that an extension does not.

US activity the same day shows how different the timelines can be. The FDA accepted Intellia's BLA for its one-time hereditary angioedema gene-editing therapy, lonvoguran ziclumeran, with priority review and a goal date of 10 March 2027. According to the company, the agency does not currently plan an advisory committee. NeOnc has a Type B meeting in early January 2027 to test whether Phase 2a data can support a 505(b)(2) application for intranasal NEO100. Cingulate expects to resubmit its CTx-1301 application between December 2026 and January 2027, after a June complete response letter that raised manufacturing questions. These are separate programmes in separate regions, and none bears directly on Zybrivo. Together they show that approval timing depends on the pathway as much as on the product.

Who is affected

Fortvita's regulatory and quality teams now turn to the Commission decision phase. That includes finalising product information translations and meeting any post-opinion commitments. Pharmacovigilance teams need EU risk management and safety reporting arrangements in place by launch. Competitors with PD-1 or PD-L1 products in NSCLC should read the EPAR carefully when it appears, particularly for labelled population wording, since it determines which patients fall under the new indication.

Market-access teams should note that a CHMP opinion starts national pricing and reimbursement groundwork but does not complete it. Reimbursement timing varies by member state. The records contain nothing on Zybrivo's launch plans or pricing, so those remain unknown.

What to watch

The first marker is the Commission decision, which would confirm the indication wording and any conditions. The second is publication of the EPAR and product information, which should show the evidence base the committee relied on, any restrictions on the indication, and the safety language. Neither is in the current records.

Beyond that, watch for Fortvita's statements on launch markets and for whether other regulators in the records' coverage, such as the FDA, take up the product. The records say nothing about filings outside the EU, so no inference should be drawn.